Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1INDIV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Hematologic Neoplasms 2Urinary Bladder Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Kidney Neoplasms 1Hodgkin Disease 1Genetic Diseases, Inborn 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

aldesleukin 65Cyclophosphamide 45fludarabine phosphate 30fludarabine 27Interleukin-2 24incomplete Freund's adjuvant 22Ipilimumab 17Specimen Handling 14MART-1 Antigen 14CTLA-4 Antigen 14sargramostim 13Magnetic Resonance Spectroscopy 13Biopsy 13montanide ISA 51 11Nivolumab 11Filgrastim 11Sorafenib 10Interferon-alpha 9trametinib 8pembrolizumab 8dabrafenib 8Sirolimus 7Bevacizumab 7temsirolimus 6Temozolomide 6Taxes 5Paclitaxel 5Introns 5Gene Expression Profiling 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Melanoma × keyhole-limpet hemocyanin × Clear all
NCT00091143 2013-04-04

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡